Abstract
Rabies is a zoonose affecting wild and domestic animals and transmitted to humans through bites or scratches, causing over 60,000 human deaths, annually. The disease results from the transmission of a neurotropic virus leading to invariably deadly encephalitis. The post-exposure prophylaxis consists of careful washing and disinfection of the wound, antibiotherapy and tetanus prophylaxis when needed. Furthermore, rabies vaccine and rabies immunoglobulin [RIG] administration should be applied according to the type of wound, and the animal involved, according to the WHO protocols that are regularly updated. Unfortunately it is sometimes difficult to obtain RIG in some countries due to their high cost, leading to suboptimal treatment and possible death. Also, observance can be weak, due to the number of repeated visits required with protocols [up to five visits over 28 days]. These limitations justify research on new vaccines which were not conclusive at the moment. New RIGs are under development, including a monoclonal antibody cocktail which is more promising in a near future. Finally, vaccination protocols are in the way of being shortened in given conditions. Further studies are needed to validate these new practices.
Keywords: Humans, post exposure prophylaxis, rabies immunoglobulin, rabies, recommendations, vaccines.
Infectious Disorders - Drug Targets
Title:Current Perspectives on Rabies Postexposure Prophylaxis
Volume: 15 Issue: 1
Author(s): Agathe Blaise and Philippe Gautret
Affiliation:
Keywords: Humans, post exposure prophylaxis, rabies immunoglobulin, rabies, recommendations, vaccines.
Abstract: Rabies is a zoonose affecting wild and domestic animals and transmitted to humans through bites or scratches, causing over 60,000 human deaths, annually. The disease results from the transmission of a neurotropic virus leading to invariably deadly encephalitis. The post-exposure prophylaxis consists of careful washing and disinfection of the wound, antibiotherapy and tetanus prophylaxis when needed. Furthermore, rabies vaccine and rabies immunoglobulin [RIG] administration should be applied according to the type of wound, and the animal involved, according to the WHO protocols that are regularly updated. Unfortunately it is sometimes difficult to obtain RIG in some countries due to their high cost, leading to suboptimal treatment and possible death. Also, observance can be weak, due to the number of repeated visits required with protocols [up to five visits over 28 days]. These limitations justify research on new vaccines which were not conclusive at the moment. New RIGs are under development, including a monoclonal antibody cocktail which is more promising in a near future. Finally, vaccination protocols are in the way of being shortened in given conditions. Further studies are needed to validate these new practices.
Export Options
About this article
Cite this article as:
Blaise Agathe and Gautret Philippe, Current Perspectives on Rabies Postexposure Prophylaxis, Infectious Disorders - Drug Targets 2015; 15 (1) . https://dx.doi.org/10.2174/1871526515666150320161630
DOI https://dx.doi.org/10.2174/1871526515666150320161630 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Redox-Driven Events in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection and their Clinical Implications
Current HIV Research Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Neurotrophins - From Pathophysiology to Treatment in Alzheimers Disease
Current Alzheimer Research Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Treatment of Severe Cases of Pandemic (H1N1) 2009 Influenza: Review of Antivirals and Adjuvant Therapy
Recent Patents on Anti-Infective Drug Discovery Simultaneous HPLC Determination of Metronidazole and Spiramycin in Plasma and Brain of Mouse
Current Pharmaceutical Analysis Design, Synthesis and Biological Evaluation of Antipicornaviral Pyrrole-Containing Peptidomimetics
Protein & Peptide Letters Targeted Oncolytic Herpes Simplex Viruses for Aggressive Cancers
Current Pharmaceutical Biotechnology Infectious Causes of Childhood Disability
Infectious Disorders - Drug Targets Galectin-9 in Cancer Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Re-Balancing of Inflammation and Aβ Immunity as a Therapeutic for Alzheimers Disease-View from the Bedside
CNS & Neurological Disorders - Drug Targets Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Therapeutic Opportunities for Trophic Factors in Brain Inflammation
Current Pharmaceutical Analysis Development and Production of Commercial Therapeutic Monoclonal Antibodies in Mammalian Cell Expression Systems: An Overview of the Current Upstream Technologies
Current Pharmaceutical Biotechnology Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS
Current Neuropharmacology Detailed Molecular Biochemistry for Novel Therapeutic Design Against Nipah and Hendra Virus: A Systematic Review
Current Molecular Pharmacology Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism